PMID- 31772942
OWN - NLM
STAT- MEDLINE
DCOM- 20200421
LR  - 20200421
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2019
DP  - 2019
TI  - Impact of Hypoglycemia on Health-Related Quality of Life among Type 2 Diabetes: A 
      Cross-Sectional Study in Thailand.
PG  - 5903820
LID - 10.1155/2019/5903820 [doi]
LID - 5903820
AB  - Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases. 
      Patients are generally advised lifestyle changes with antihyperglycemic agents 
      prescribed. The major drawback of prescribing antihyperglycemic agents is the 
      risk of hypoglycemia which subsequently impacts on health-related quality of life 
      (HRQoL). This study is aimed at examining association between previous history of 
      hypoglycemia and HRQoL. The study was a multicenter cross-sectional study, 
      conducted from February 2013 to March 2015 at 5 tertiary care hospitals in 
      Thailand (Srinagarind, Phramongkutklao, Ramathibodi, King Chulalongkorn Memorial, 
      and Siriraj hospitals). The study population were males or females diagnosed with 
      type 2 DM according to ADA criteria, 30 years of age or older, who had been 
      treated with sulfonylurea (SU) monotherapy or SU and metformin combination for at 
      least 6 months. Prespecified medical factors were extracted from medical records 
      12 months prior to patients' enrolment. The experience of hypoglycemia 
      questionnaire was used to collect and measure severity of hypoglycemia 
      experienced during the previous 6 months. HRQoL was assessed using the 3-level 
      version of EuroQol-5-dimension (EQ-5D-3L) and visual analogue scale (EQ-VAS) 
      questionnaires. Of 659 eligible patients surveyed, 202 patients (30.65%) had 
      experienced symptoms of hypoglycemia. HRQoL was significantly lower among 
      patients reporting at least one of hypoglycemic symptoms, measured by EQ-VAS 
      scores (mean +/- SD; 73.66 +/- 13.18, 73.56 +/- 15.10, or 68.93 +/- 14.76 vs. 77.01 +/- 
      13.02, one-way ANOVA; p = 0.006) and EQ-5D-3L index scores (0.62 +/- 0.47, 0.68 +/- 
      0.38, or 0.58 +/- 0.51 vs. 0.79 +/- 0.31, one-way ANOVA; p < 0.001) for mild, 
      moderate, or severe/very severe hypoglycemic patients compared with patients 
      without hypoglycemic symptoms. After adjusting for confounding factors in a 
      multiple linear regression model, patients with hypoglycemic symptoms either 
      mild, moderate, or severe/very severe demonstrated significantly higher 
      impairment for EQ-VAS and EQ-5D indexes than those who did not experience 
      hypoglycemic symptoms. In conclusion, our study showed decreased HRQoL determined 
      by EQ-5D and EQ-VAS in patients reporting symptoms of hypoglycemia compared with 
      patients not reporting hypoglycemic symptoms, relative to severity of 
      hypoglycemia.
CI  - Copyright (c) 2019 Thongchai Pratipanawatr et al.
FAU - Pratipanawatr, Thongchai
AU  - Pratipanawatr T
AUID- ORCID: 0000-0002-5480-6822
AD  - Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen 
      University, Khon Kaen 40002, Thailand.
FAU - Satirapoj, Bancha
AU  - Satirapoj B
AUID- ORCID: 0000-0002-8881-0942
AD  - Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok 
      10400, Thailand.
FAU - Ongphiphadhanakul, Boonsong
AU  - Ongphiphadhanakul B
AUID- ORCID: 0000-0002-3558-1621
AD  - Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol 
      University, Bangkok 10400, Thailand.
FAU - Suwanwalaikorn, Sompongse
AU  - Suwanwalaikorn S
AUID- ORCID: 0000-0003-4321-5063
AD  - Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial 
      Hospital, Chulalongkorn University, Bangkok 10330, Thailand.
FAU - Nitiyanant, Wannee
AU  - Nitiyanant W
AD  - Department of Medicine, Siriraj Hospital, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20191023
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - *Blood Glucose
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/psychology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Hypoglycemia/*blood/chemically induced/psychology
MH  - Hypoglycemic Agents/adverse effects/therapeutic use
MH  - Male
MH  - Metformin/adverse effects/therapeutic use
MH  - Middle Aged
MH  - *Quality of Life
MH  - Sulfonylurea Compounds/adverse effects/therapeutic use
MH  - Surveys and Questionnaires
MH  - Thailand
PMC - PMC6854960
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper. Although MSD (Thailand) Ltd. supported the study 
      funding, the study was conducted and the study results were interpreted without 
      the influence of the pharmaceutical company.
EDAT- 2019/11/28 06:00
MHDA- 2020/04/22 06:00
PMCR- 2019/10/23
CRDT- 2019/11/28 06:00
PHST- 2019/05/11 00:00 [received]
PHST- 2019/09/27 00:00 [accepted]
PHST- 2019/11/28 06:00 [entrez]
PHST- 2019/11/28 06:00 [pubmed]
PHST- 2020/04/22 06:00 [medline]
PHST- 2019/10/23 00:00 [pmc-release]
AID - 10.1155/2019/5903820 [doi]
PST - epublish
SO  - J Diabetes Res. 2019 Oct 23;2019:5903820. doi: 10.1155/2019/5903820. eCollection 
      2019.